prof. dr. H.J. (Hiddo) Lambers Heerspink

Clinical Pharmacologist

Faculty of Medical Sciences

Telephone:

+31 50 361 7859

E-mail:

h.j.lambers.heerspink umcg.nl

ORCID Research Portal

Publications

Authors' Reply: Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence

Heerspink, H. J. L. & Smeijer, J. D., Feb-2025, In: Journal of the American Society of Nephrology. 36, 2, p. 324 1 p.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials

Chatur, S., Vaduganathan, M., Fletcher, R. A., Perkovic, V., Heerspink, H., Arnott, C., Pollock, C., Mahaffey, K. W., Neal, B., Jardine, M., Solomon, S. D. & Neuen, B. L., 23-Jan-2025, (E-pub ahead of print) In: European Journal of Heart Failure.

Research output: Contribution to journal › Article › Academic › peer-review

Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

Siriwardana, A., Buizen, L., Jun, M., Kotwal, S., Arnott, C., Jardine, M. J., Levin, A., Heerspink, H. J. L., Charytan, D. M., Pollock, C., Perkovic, V. & Neuen, B. L., Apr-2025, In: Diabetes, Obesity and Metabolism. 27, 4, p. 1972-1979 8 p.

Research output: Contribution to journal › Article › Academic › peer-review

Compositions and methods for treating and preventing kidney disease

Kretzler, M. (Inventor), Bjornstad, P. (Inventor), Ju, W. (Inventor), Nair, V. (Inventor) & Heerspink, H. (Inventor), 30-Jan-2025, Patent No. WO2025024212, 18-Jul-2024, Priority date 26-Jul-2023

Research output: Patent

Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy”

Heerspink, H. J. L., Jardine, M., Kohan, D. E., Lafayette, R. A., Levin, A., Liew, A., Zhang, H., Noronha, I., Trimarchi, H., Hou, F. F., Renfurm, R., Gray, T., Camargo, M. & Barratt, J., Apr-2025, In: Kidney International Reports. 10, 4, p. 1302 1 p.

Research output: Contribution to journal › Erratum

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

FIND-CKD investigators, Heerspink, H. J. L., Agarwal, R., Bakris, G. L., Cherney, D. Z. I., Lam, C. S. P., Neuen, B. L., Sarafidis, P. A., Tuttle, K. R., Wanner, C., Brinker, M. D., Dizayee, S., Kolkhof, P., Schloemer, P., Vesterinen, P. & Perkovic, V., Feb-2025, In: Nephrology Dialysis Transplantation. 40, 2, p. 308-319 12 p.

Research output: Contribution to journal › Article › Academic › peer-review

Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow-up of the PRIORITY study

the PRIORITY Study group, Jan-2025, In: Diabetes, Obesity and Metabolism. 27, 1, p. 387-393 7 p.

Research output: Contribution to journal › Article › Academic › peer-review

Endothelin receptor antagonists in chronic kidney disease

Smeijer, J. D., Kohan, D. E., Dhaun, N., Noronha, I. L., Liew, A. & Heerspink, H. J. L., Mar-2025, In: Nature Reviews Nephrology. 21, p. 175–188 14 p.

Research output: Contribution to journal › Review article › peer-review

Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial

Apperloo, E. M., Heerspink, H. J. L., Van Der Aart, A. B., Rouw, D., Van Raalte, D. H., Hoogenberg, K., Jongs, N. & Muskiet, M. H. A., Mar-2025, In: Diabetes Care. 48, 3, p. e22-e24

Research output: Contribution to journal › Letter › Academic › peer-review